---
title: "HeYu's independently developed new drug has received FDA Fast Track designation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275383105.md"
description: "ABBISKO-B announced that its self-developed FGFR4 inhibitor Irpagratinib (ABSK-011) has received Fast Track designation from the U.S. FDA for patients with hepatocellular carcinoma who have previously received immune checkpoint inhibitors and multi-target kinase inhibitors and have FGF19 overexpression. This will accelerate its global clinical development and regulatory review process. ABBISKO will continue to advance the international clinical layout of this project, committed to providing precise and effective innovative treatment solutions for global HCC patients"
datetime: "2026-02-10T00:51:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275383105.md)
  - [en](https://longbridge.com/en/news/275383105.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275383105.md)
---

# HeYu's independently developed new drug has received FDA Fast Track designation

Abbisko-B (02256.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Abbisko's independently developed highly selective small molecule FGFR4 inhibitor Irpagratinib (ABSK-011) Fast Track Designation (FTD) for the treatment of patients with hepatocellular carcinoma (HCC) who have previously received immune checkpoint inhibitors (ICIs) and multi-target kinase inhibitors (mTKIs) and have FGF19 overexpression.

This will help accelerate the clinical development and regulatory review process of Irpagratinib globally. Abbisko will continue to advance the international clinical layout of this project, committed to providing more precise and effective innovative treatment solutions for HCC patients worldwide

### Related Stocks

- [02256.HK](https://longbridge.com/en/quote/02256.HK.md)

## Related News & Research

- [Abbisko Advances FGFR4 Inhibitor Irpagratinib With First U.S. Patient Dosed in Global HCC Trial](https://longbridge.com/en/news/275528457.md)
- [20:00 ETAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases](https://longbridge.com/en/news/286830151.md)
- [First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial](https://longbridge.com/en/news/286888745.md)
- [TransThera reports promising tinengotinib results in advanced solid tumors](https://longbridge.com/en/news/286670762.md)
- [Transcenta Gains Boost as Inhibrx’s Ozekibart Data and FDA Filing Strengthen Greater China Cancer Franchise](https://longbridge.com/en/news/287168572.md)